Boston Scientific's WatchmanFLX Trial Results Lead to Stock Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy BSX?
Source: seekingalpha
- Trial Overview: Boston Scientific's WatchmanFLX left atrial appendage closure device trial met primary and secondary endpoints in non-valvular atrial fibrillation patients, yet the stock fell 9% on Monday, indicating a negative market reaction.
- Primary Endpoint Comparison: The CHAMPION-AF study revealed that the occurrence of stroke, cardiovascular or unexplained death, and systemic embolism was non-inferior between Watchman and oral anticoagulants, with rates of 5.7% versus 4.8%, suggesting comparable efficacy.
- Safety Analysis: The primary safety endpoint showed that non-procedural major and clinically relevant non-major bleeding rates were significantly lower in the Watchman cohort at 10.9% compared to 19% in the anticoagulant group, highlighting its safety advantage.
- Investor Confidence: Despite a slightly higher ischemic stroke rate in Watchman patients (3.2% vs. 2%), analysts remain optimistic, believing these results will support an increase in WATCHMAN procedure volumes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 62.930
Low
94.00
Averages
108.14
High
132.00
Current: 62.930
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Schedules Q1 2026 Earnings Call
- Earnings Call Announcement: Boston Scientific Corporation will host a conference call on April 22, 2026, at 8:00 a.m. ET to discuss its financial results for Q1 2026, providing key business highlights and financial data.
- Executive Leadership: The call will be led by Chairman and CEO Mike Mahoney alongside Executive VP and CFO Jon Monson, ensuring that investors receive insights directly from top management regarding the company's financial performance.
- Pre-Call Financial Release: The company plans to issue a news release announcing its Q1 financial results prior to the call, aiming to provide timely information that helps investors understand the company's financial health and future outlook.
- Live Webcast and Replay: The event will be accessible via a live webcast, with a replay available on Boston Scientific's investor website, ensuring that investors who cannot attend in real-time can still access important information.
See More
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made positive statements while concealing the unsustainable growth of its U.S. Electrophysiology segment, resulting in investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved significant settlements, recovering over $438 million for investors in 2019 alone, highlighting its leadership in the field.
- Investor Guidance: Investors are advised to carefully select experienced legal counsel rather than firms that merely act as intermediaries, ensuring they receive effective legal support in the class action.
See More
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Robbins LLP reminds all investors who purchased Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025, and February 3, 2026, that a class action has been filed to protect shareholder rights and seek compensation.
- False Information Allegations: The lawsuit alleges that Boston Scientific misled investors during this period by claiming reliable information regarding the company's revenue outlook, while in reality, it faced new competitors that diminished its market share in U.S. electrophysiology.
- Significant Stock Price Drop: On February 4, 2026, Boston Scientific announced disappointing fourth quarter and full year 2025 results, causing its stock price to plummet from $91.62 to $75.50, a decline of over 17%, reflecting market concerns about the company's growth potential.
- Shareholder Action Guidance: Shareholders can submit their applications by May 4, 2026, to serve as lead plaintiffs in the class action, representing other shareholders in the litigation, and those who choose not to participate can remain absent class members while still being eligible for recovery.
See More
Mixed Close for US Stocks as Nasdaq Hits 7.75-Month Low Amid Middle East Tensions
- Divergent Market Performance: On Monday, the S&P 500 index fell by 0.39%, while the Nasdaq 100 hit a 7.75-month low, indicating market concerns over the Middle East situation, particularly exacerbated by a sell-off in chip stocks, which negatively impacted investor confidence.
- Declining Bond Yields: The 10-year T-note yield dropped by 8 basis points to 4.34%, reflecting market fears that the ongoing war in the Middle East could lead to fuel shortages, potentially suppressing expectations for Fed rate hikes and highlighting economic growth uncertainties.
- Rising Crude Oil Prices: Crude oil prices surged over 3% to a three-week high due to Iranian attacks on the Strait of Hormuz, indicating severe threats to global energy supply chains, which could lead to soaring prices in the future and impact the global economy.
- Weak Manufacturing Activity: The Dallas Fed manufacturing activity survey fell to -0.2, below the expected 2.0, reflecting signs of economic slowdown that could influence corporate investment decisions and future economic growth.
See More
Boston Scientific Shares Drop 9.02% Amid Trial Update
- Significant Stock Decline: Boston Scientific (BSX) closed at $62.92 on Monday, down 9.03%, reflecting investor concerns over new clinical trial information regarding its heart implant, which has weakened market confidence in the company's future growth prospects.
- Surge in Trading Volume: The trading volume reached 39.9 million shares, approximately 163% above the three-month average of 15.2 million shares, indicating heightened market attention to the company's news, which may lead to increased short-term price volatility.
- Clinical Trial Update: Boston Scientific announced that its CHAMPION-AF trial met all safety and efficacy endpoints for the Watchman FLX heart implant; however, analysts expressed disappointment, suggesting that growth potential may not accelerate as anticipated.
- Investor Sentiment Analysis: While analysts maintained outperform ratings on Boston Scientific, the stock has dropped 38% over the past year, and with a current P/E ratio of just 18 times forward earnings, investors should view the company's future growth potential rationally and avoid overreacting to a single trial outcome.
See More
Boston Scientific Shares Drop 9.03% Amid Trial Update
- Clinical Trial Update: Boston Scientific announced that its CHAMPION-AF trial for the Watchman heart implant met all safety and efficacy endpoints, yet analysts expressed disappointment, suggesting that growth may not accelerate as anticipated, which could impact investor sentiment negatively.
- Surge in Trading Volume: On Monday, trading volume surged to 39.9 million shares, approximately 163% above the three-month average of 15.2 million shares, indicating strong investor reaction to the trial update despite the stock's 9.03% decline.
- Stock Performance: Boston Scientific closed at $62.92, reflecting a 38% drop over the past year, with a forward P/E ratio of 18, suggesting that the stock may be reasonably priced after significant volatility in its performance.
- Market Context: The decline in Boston Scientific's stock aligns with broader pressures in the medical device sector, as peers Medtronic and Stryker also experienced losses, while the S&P 500 and Nasdaq indices fell by 0.39% and 0.73%, respectively.
See More
Boston Scientific Schedules Q1 2026 Earnings Call
- Earnings Call Announcement: Boston Scientific Corporation will host a conference call on April 22, 2026, at 8:00 a.m. ET to discuss its financial results for Q1 2026, providing key business highlights and financial data.
- Executive Leadership: The call will be led by Chairman and CEO Mike Mahoney alongside Executive VP and CFO Jon Monson, ensuring that investors receive insights directly from top management regarding the company's financial performance.
- Pre-Call Financial Release: The company plans to issue a news release announcing its Q1 financial results prior to the call, aiming to provide timely information that helps investors understand the company's financial health and future outlook.
- Live Webcast and Replay: The event will be accessible via a live webcast, with a replay available on Boston Scientific's investor website, ensuring that investors who cannot attend in real-time can still access important information.
See More
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made positive statements while concealing the unsustainable growth of its U.S. Electrophysiology segment, resulting in investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved significant settlements, recovering over $438 million for investors in 2019 alone, highlighting its leadership in the field.
- Investor Guidance: Investors are advised to carefully select experienced legal counsel rather than firms that merely act as intermediaries, ensuring they receive effective legal support in the class action.
See More
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Robbins LLP reminds all investors who purchased Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025, and February 3, 2026, that a class action has been filed to protect shareholder rights and seek compensation.
- False Information Allegations: The lawsuit alleges that Boston Scientific misled investors during this period by claiming reliable information regarding the company's revenue outlook, while in reality, it faced new competitors that diminished its market share in U.S. electrophysiology.
- Significant Stock Price Drop: On February 4, 2026, Boston Scientific announced disappointing fourth quarter and full year 2025 results, causing its stock price to plummet from $91.62 to $75.50, a decline of over 17%, reflecting market concerns about the company's growth potential.
- Shareholder Action Guidance: Shareholders can submit their applications by May 4, 2026, to serve as lead plaintiffs in the class action, representing other shareholders in the litigation, and those who choose not to participate can remain absent class members while still being eligible for recovery.
See More
Mixed Close for US Stocks as Nasdaq Hits 7.75-Month Low Amid Middle East Tensions
- Divergent Market Performance: On Monday, the S&P 500 index fell by 0.39%, while the Nasdaq 100 hit a 7.75-month low, indicating market concerns over the Middle East situation, particularly exacerbated by a sell-off in chip stocks, which negatively impacted investor confidence.
- Declining Bond Yields: The 10-year T-note yield dropped by 8 basis points to 4.34%, reflecting market fears that the ongoing war in the Middle East could lead to fuel shortages, potentially suppressing expectations for Fed rate hikes and highlighting economic growth uncertainties.
- Rising Crude Oil Prices: Crude oil prices surged over 3% to a three-week high due to Iranian attacks on the Strait of Hormuz, indicating severe threats to global energy supply chains, which could lead to soaring prices in the future and impact the global economy.
- Weak Manufacturing Activity: The Dallas Fed manufacturing activity survey fell to -0.2, below the expected 2.0, reflecting signs of economic slowdown that could influence corporate investment decisions and future economic growth.
See More
Boston Scientific Shares Drop 9.02% Amid Trial Update
- Significant Stock Decline: Boston Scientific (BSX) closed at $62.92 on Monday, down 9.03%, reflecting investor concerns over new clinical trial information regarding its heart implant, which has weakened market confidence in the company's future growth prospects.
- Surge in Trading Volume: The trading volume reached 39.9 million shares, approximately 163% above the three-month average of 15.2 million shares, indicating heightened market attention to the company's news, which may lead to increased short-term price volatility.
- Clinical Trial Update: Boston Scientific announced that its CHAMPION-AF trial met all safety and efficacy endpoints for the Watchman FLX heart implant; however, analysts expressed disappointment, suggesting that growth potential may not accelerate as anticipated.
- Investor Sentiment Analysis: While analysts maintained outperform ratings on Boston Scientific, the stock has dropped 38% over the past year, and with a current P/E ratio of just 18 times forward earnings, investors should view the company's future growth potential rationally and avoid overreacting to a single trial outcome.
See More
Boston Scientific Shares Drop 9.03% Amid Trial Update
- Clinical Trial Update: Boston Scientific announced that its CHAMPION-AF trial for the Watchman heart implant met all safety and efficacy endpoints, yet analysts expressed disappointment, suggesting that growth may not accelerate as anticipated, which could impact investor sentiment negatively.
- Surge in Trading Volume: On Monday, trading volume surged to 39.9 million shares, approximately 163% above the three-month average of 15.2 million shares, indicating strong investor reaction to the trial update despite the stock's 9.03% decline.
- Stock Performance: Boston Scientific closed at $62.92, reflecting a 38% drop over the past year, with a forward P/E ratio of 18, suggesting that the stock may be reasonably priced after significant volatility in its performance.
- Market Context: The decline in Boston Scientific's stock aligns with broader pressures in the medical device sector, as peers Medtronic and Stryker also experienced losses, while the S&P 500 and Nasdaq indices fell by 0.39% and 0.73%, respectively.
See More
